Global Bipolar Disorder Market Outlook To 2025: Key Drugs Class (Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety), Mechanism of Action (Dopaminergic neurotransmission inhibition, Selective serotonin reuptake inhibitor, Serotonin-norepinephrine reuptake inhibitor, Tricyclic antidepressants, Monoamine oxidase inhibitor, Benzodiazepines, Beta blockers, Others), Regional Segmentation, Competitive Dynamics, M&A Insights, Pricing Analysis (OPP, IPP, RAP), And Segment Forecast

$5,650.00$12,650.00

Clear
  • Report Description
  • Table of Content
  • Highlight
  • Research Methodology
  • Request Free Sample

The global Bipolar Disorder Market was valued at $5.8 Billion in 2017 and is forecast to grow at a modest3.1 % CAGR between 2018 and 2025, culminating in 2025 global sales of $XXX.64 Billion.

 

Symptoms of bipolar disorder is a mental illness characterized by an extreme shift in mood, can include an extremely elevated mood called mania. It can have an episode of depression. People with bipolar disorder can have serious trouble managing daily life at office, school or work. As per the national institute of mental health (NIMH), 2.8% of U.S. adult have diagnosed with bipolar disorder and 4.4% have experienced at sometime in their lives.

 

There are 3 main symptoms of bipolar disorder as mania, hypomania, and depression. Mania will lead to emotional high as unprotected sex, drug use etc. whereas hypomania will cause deep sadness, hopelessness, lack of interest in activities and suicidal thoughts. During the study, we observed a steep rise in the incidence of bipolar disorder in 5 states of USA, Germany, UK, Greece, Italy, and Spain. Though we have not noticed any major difference in trend between male and female, female will have a more frequent relapse due to hormonal changes.

 

Though the cause of bipolar disorder is not properly known to physicians, possible factors could be your genetics, abnormalities in the brainand environmental factor. There is no cure for bipolar disorder, but medications are there to control symptoms. It might need a combination of medication, physiotherapy, and psychoeducation.

 

Global Bipolar Disorder Market Outlook To 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Bipolar Disorder Drugs”

 

Estimated Average bipolar disorder drugs cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Product affordability and access to healthcare facilities are key variables impacting the market growth. The high demand for bipolar disorder drugs and other physiotherapy techniques in emerging nations is expected to drive the usage rates. The growing need for early diagnosis and government initiative is expected to lower the costs and improve the purchasing power of patients in this region.

 

Bipolar Disorder Market by “Drug Class”

 

Based on drug class, the market is segmented as Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety. Usage of tricyclic antidepressants for bipolar disorder has declined over the years due to its side effect profile. More than 60% of the market is dominated by antipsychotic drugs such as Aripiprazole (Abilify), Asenapine (Saphris), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal) etc. Some of the prominent mood stabilizers for bipolar disorder are Lithium, Valproate (Depakote), Carbamazepine (Tegretol), Gabapentin (Neurontin) etc. Carbamazepine is not approved by U.S. FDA but extensively used for bipolar disorder. Anticonvulsants work by calming hyperactivity and prescribed alone or in combination with antipsychotic drugs.

 

Bipolar Disorder Market by “Mechanism of Action”

 

Based on the mechanism of actions, the market is segmented as Dopaminergic neurotransmission inhibition, Selective serotonin reuptake inhibitor (SSRI), Serotonin-norepinephrine reuptake inhibitor (SNRI), Tricyclic antidepressants, Monoamine oxidase inhibitor, Benzodiazepines, Beta blockers, Others. All antipsychotic drugs dominating treatment for bipolar disorder by Dopaminergic neurotransmission Inhibition. Selective serotonin reuptake inhibitors (SSRIs) ease depression by increasing serotonin level in the brain. Benzodiazepines are not considered as the1st line of treatment but prescribed in combination with other drugs to control the maniac symptoms.

 

Regional Segmentation

 

In 2017, North America was the leading region by revenue owing to factors such as thepresence of well-developed hospital and diagnostic center network, thehighrate of diagnosis, transparent process for availing reimbursement, and high emphasis on research & development. The U.S. alone accounts for over 80% share in North America. The U.S. spends nearly 3.2 trillion dollars or 17% of GDP toward healthcare expenditure, to provide the best possible infrastructure and technology solutions to patients living in the region.

 

Asia Pacific is expected to register the maximum CAGR of over 7.2% over the forecast period with greater demand from geriatric population of China. High unmet needs, growing healthcare expenditure, and an increasingnumber of hospitals and psychiatric centers are anticipated to significantly drive the demand for bipolar disorder drugs over the next few years.

 

Top Players & Company Share

 

Key players operating in the market include Pfizer Inc., Janssen Pharmaceuticals,Glaxo SmithKline (GSK), AstraZeneca, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc. and Otsuka Holdings Co. Ltd.Due to high entry barriers, such as high capital costs, technology and IPR rights, and brand building efforts, the number of new entrants is usually low in the market. However, the startups are working on integrating connectivity technologies, newer designing and other niche areas to improve the product and service offerings.

The launch of Vraylarfrom Allergan in 2016 for bipolar disorder shows the attractiveness of this market.

 

Market Segmentation

 

Bipolar Disorder Market byDrug Class(Revenue, Million, 2014 – 2025)

  • Mood stabilizer
  • Anticonvulsant
  • Antipsychotic
  • Antidepressant
  • Antianxiety

 

Bipolar Disorder Market by Mechanism of Action, (Revenue, USD Million, 2014 – 2025)

  • Dopaminergic neurotransmission inhibition
  • Selective serotonin reuptake inhibitor
  • Serotonin-norepinephrine reuptake inhibitor
  • Tricyclic antidepressants
  • Monoamine oxidase inhibitor
  • Benzodiazepines
  • Beta-blockers
  • Others

Bipolar Disorder Market Regional Outlook (Revenue, USD Million, 20124- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

Bipolar Disorder Market, Bipolar Disorder Market Analytics, Bipolar Disorder Market Share, Bipolar Disorder Market Research, Bipolar Disorder Market Forecast, Bipolar Disorder Market Insight, Bipolar Disorder Market Trend, Bipolar Disorder Market Value,Bipolar Disorder Market Size, Bipolar Disorder Market Analysis, Bipolar Disorder Market Survey, Bipolar Disorder Market Research Report

Chapter 1 Methodology and Scope

  • Research Methodology
  • Research Scope & Assumptions
  • List of Data Sources

Chapter 2 Executive Summary

Chapter 3 Bipolar DisorderDrugsMarketOverview

  • Global Disease Landscape
  • Global Healthcare Expenditure

Chapter 4 Bipolar DisorderDrugsIndustry Outlook

  • Market Overview
  • Market Segmentation
  • Market Size and Growth Prospects
  • Leading Brand Dynamics
  • Key Market Drivers
    • Increasing Diagnosis of Bipolar Disorder
    • Government Support
    • Robust product pipeline and increased R&D
  • Key Market Challenges
    • Side effect profile of treatment drugs
    • Lack of awareness for bipolar disorder
  • Key Opportunities Prioritized
  • Industry Analysis - Porter’s
  • Bipolar DisorderMarket-PESTEL Analysis

Chapter 5: -Bipolar DisorderDrugs Market by “Drug Class” (USD Million)

Bipolar DisorderDrugs Market Landscape by Drug Class- 2017 & 2025
  • Mood stabilizer
    • Market Landscape Analysis, 2017-2025
  • Anticonvulsant
    • Market Landscape Analysis, 2017-2025
  • Antipsychotic
    • Market Landscape Analysis, 2017-2025
  • Antidepressant
    • Market Landscape Analysis, 2017-2025
  • Antianxiety
    • Market Landscape Analysis, 2017-2025
 

Chapter 6: -Bipolar Disorder Drugs Market by “Mechanism of Action” (USD Million)

  • Bipolar Disorder DrugsMarket Landscape by Mechanism of Action- 2017 & 2025
  • Dopaminergic neurotransmission inhibition
    • Market Landscape Analysis, 2017-2025
  • Selective serotonin reuptake inhibitor
    • Market Landscape Analysis, 2017-2025
  • Serotonin-norepinephrine reuptake inhibitor
    • Market Landscape Analysis, 2017-2025
  • Tricyclic antidepressants
    • Market Landscape Analysis, 2017-2025
  • Monoamine oxidase inhibitor
    • Market Landscape Analysis, 2017-2025
  • Benzodiazepines
    • Market Landscape Analysis, 2017-2025
  • Beta blockers
    • Market Landscape Analysis, 2017-2025
  • Others
    • Market Landscape Analysis, 2017-2025
 

Chapter 9: Regional Market Outlook

Bipolar Disorder DrugsMarket Landscape by Region- 2017
  • North America Market Landscape Analysis, 2017-2025 (USD Mn)
    • U.S. Market Landscape Analysis, 2017-2025
    • Canada Market Landscape Analysis-2017-2025
  • Europe Market Landscape Analysis, 2017-2025 (USD Mn)
    • K Market Landscape Analysis, 2017-2025
    • Germany Market Landscape Analysis, 2017-2025
    • France Market Landscape Analysis, 2017-2025
    • Italy Market Landscape Analysis, 2017-2025
    • Spain Market Landscape Analysis, 2017-2025
  • Latin America Market Landscape Analysis, 2017-2025 (USD Mn)
    • Brazil Market Landscape Analysis, 2017-2025
    • Mexico Market Landscape Analysis, 2017-2025
    • Colombia Market Landscape Analysis, 2017-2025
  • Asia PacificMarket Landscape Analysis, 2017-2025 (USD Mn)
    • Japan Market Landscape Analysis, 2017-2025
    • China Market Landscape Analysis, 2017-2025
    • India Market Landscape Analysis, 2017-2025
  • Middle East & Africa Market Landscape Analysis, 2014-2025 (USD Mn)
    • Saudi Arabia Market Landscape Analysis, 2014-2025
    • South AfricaMarket Landscape Analysis, 2014-2025
 

Chapter 10: Pricing Analysis

  Optimal Price Points (OPP), Indifference price points (IPP) and Range of Acceptable Prices and (RAP) of leading brands by Region- 2017
  • North America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • U.S. Pricing Analysis-2017
    • Canada Pricing Analysis-2017
  • Europe Pricing Analysis (OPP, IPP, and RAP - 2017)
    • UK Pricing Analysis-2017
    • Germany Pricing Analysis-2017
    • France Pricing Analysis-2017
    • Italy Pricing Analysis-2017
    • Spain Pricing Analysis-2017
  • Latin America Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Brazil Pricing Analysis-2017
    • Mexico Pricing Analysis-2017
    • Colombia Pricing Analysis-2017
  • Asia Pacific Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Japan Pricing Analysis-2017
    • China Pricing Analysis-2017
    • India Pricing Analysis-2017
  • Middle East Pricing Analysis (OPP, IPP, and RAP - 2017)
    • Saudi Arabia Pricing Analysis-2017
    • South Africa Pricing Analysis-2017

Chapter 11: Bipolar Disorder DrugsPipeline Analysis

  • Executive Summary
  • Late Stage Pipeline analysis
  • Key R&D trends

Chapter 12:Bipolar Disorder DrugsMerger &Acquisition Outlook

  • Factors driving M&A in Bipolar DisorderDrugsmarket
  • Key trends and future outlook

Chapter 13: Bipolar Disorder Regulatory & Patent Outlook

  • Regulatory Landscape by Region (U.S., Europe, and RoW)
  • Patent Landscape by Region (U.S., Europe, and RoW)

Chapter 14: Competitive Landscape

  • Pfizer Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Janssen Pharmaceuticals
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Glaxo SmithKline (GSK)
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • AstraZeneca
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Eli Lilly
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Allergan Plc
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Novartis AG
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • AbbVie Inc.
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
  • Otsuka Holdings Co. Ltd
    • Company Overview
    • Financial Performance
    • Key Decision Maker
    • Product Pipeline
    • Strategic Initiative
 

List of Tables

 
  • TABLE 1 Bipolar DisorderDrugsMarket - Industry Snapshot & Key Buying Criteria, 2014 - 2025
  • TABLE 2 Global Bipolar Disorder Drugs Market, 2014 – 2025
  • TABLE 3 Global Bipolar Disorder Drugs Market Analysis by Product-2017
  • TABLE 4Global Bipolar Disorder Drugs Market Analysis by Technology-2017
  • TABLE 5 Global Bipolar Disorder Drugs Market Analysis by Application-2017
  • TABLE 7 Global Bipolar Disorder DrugsMarket Analysis by Geography-2017
  • TABLE 8Global Bipolar Disorder Drugs Market Analysis by Leading Brands-2017
  • TABLE 9Bipolar Disorder Drugs Market - Key market driver analysis
  • TABLE 10Bipolar Disorder Drugs Market - Key market restraint analysis
  • TABLE 11North America Market Bipolar DisorderDrugsLandscape Analysis, 2017-2025 (USD Mn)
  • TABLE 12U.S. Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 13Canada Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 14Europe Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 15U.K Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 16 Germany Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 17 France Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 18 Italy Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 19 Spain Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 20Latin America Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 21 Brazil Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 22 Mexico Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 20 Colombia Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 21 Asia PacificBipolar Disorder Drugs Market Landscape Analysis, 2017-2025 (USD Mn)
  • TABLE 22Japan Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 23China Bipolar Disorder Drugs Market Landscape Analysis, 2017-2025
  • TABLE 24 India Bipolar DisorderDrugsMarket Landscape Analysis, 2017-2025
  • TABLE 25North America Pricing Analysis
  • TABLE 26 North America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 27 U.S. Pricing Analysis-2017
  • TABLE 28 Canada Pricing Analysis-2017
  • TABLE 29 Europe Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 30 U.K Pricing Analysis-2017
  • TABLE 31 Germany Pricing Analysis-2017
  • TABLE 32 France Pricing Analysis-2017
  • TABLE 33 Italy Pricing Analysis-2017
  • TABLE 34 Spain Pricing Analysis-2017
  • TABLE 35 Latin America Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 36 Brazil Pricing Analysis-2017
  • TABLE 37 Mexico Pricing Analysis-2017
  • TABLE 38 Colombia Pricing Analysis-2017
  • TABLE 39 Asia Pacific Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 40 Japan Pricing Analysis-2017
  • TABLE 41 China Pricing Analysis-2017
  • TABLE 42 India Pricing Analysis-2017
  • TABLE 43 Middle East Pricing Analysis (OPP, IPP, and RAP- 2017)
  • TABLE 44 Saudi Arabia Pricing Analysis-2017
  • TABLE 45 South Africa Pricing Analysis-2017
 

List of Figures

 
  • 1 Bipolar DisorderDrugsMarket Segmentation
  • 2 Market Size & Growth Prospects
  • 3 Leading Brand Dynamics
  • 4 Penetration & Growth Prospects
  • 5 Industry Analysis – Porter’s
  • 6 Bipolar DisorderDrugsMarket – PESTEL Analysis
  • 7Bipolar DisorderDrugsMarket Share by Product Type, 2017 & 2025
  • 7Bipolar DisorderDrugsMarket Share by Drug Class, 2017 & 2025
  • 7Bipolar DisorderDrugsMarket Share by Mechanism of Action, 2017 & 2025
  • 10Bipolar DisorderDrugsMarket Share by Region, 2017 & 2025

  Key Insights Addressed:  

  • Defining market size from 2014 to 2016.
  • Estimating market growth till 2024 and consequence market forecast.
  • Identifying market drivers, restraints & future opportunities and allowing decision-maker with a range of possible outcomes and the probabilities that will occur for any choice of action.
  • Market segments and regions that will drive or lead market growth.
  • Defining Optimal Price Point (OPP) which will be accepted and recommended by maximum customers.
  • A bird’s-eye view of thecompetitive landscape and the key market players.
  • Key strategic growth driver adopted by market players. In-depth analysis of their strategies and implication on competition & growth.
    Key Findings:    
  • The global Bipolar Disorder Market was valued at $5.8 Billion in 2017 and is forecast to grow at a modest 3.1 % CAGR between 2018 and 2025, culminating in 2025 global sales of $XXX.64 Billion.
  • People with bipolar disorder can have serious trouble managing daily life at office, school or work. As per the national institute of mental health (NIMH), 2.8% of U.S. adult have diagnosed with bipolar disorder and 4.4% have experienced at some time in their lives.
  • Based on drug class, the market is segmented as Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety.
  • Based on mechanism of actions, the market is segmented as Dopaminergic neurotransmission inhibition, Selective serotonin reuptake inhibitor (SSRI), Serotonin-norepinephrine reuptake inhibitor (SNRI), Tricyclic antidepressants, Monoamine oxidase inhibitor, Benzodiazepines, Beta blockers, Others.
  • Key players operating in the market include Pfizer Inc., Janssen Pharmaceuticals, Glaxo SmithKline (GSK), AstraZeneca, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc. and Otsuka Holdings Co. Ltd

Ameri Research implies a unique methodology of published information and primary research to bring key insights to customer decision making process. Our analytics model helps us to understand the structured and unstructured information from various sources. Key steps involves in the process are as below-

    1. Analyzing Published Information- Access to large pool of paid and unpaid published information via different sources and analyzing market trend.
    2. Setting Foundation- Input from analysis of secondary sources set our foundation to market analysis and helps in setting the scope for further research. Setting the scope involves Ameri Research proprietary statistical model, discussion with industry leaders, internal brainstorming, key discussion pointers from various forums etc.
    3. Need Gap Analysis- Defining the gap between our scope and availability of information.
    4. KOL Panel Discussion- Focused Group Discussion with a structured discussion guide to fine tune the gap and deriving the factors driving/restraining the market trend.
    5. Quantitative Research- Sampling large number of industry players, Education/Research Institutes, Government bodies, NGOs, Individual acclaimed researchers and conducting the primary interview with a structured questionnaire.
    6. Data Triangulation- We apply bottom-up demand approach or top-down estimation or a combined approach to triangulate the data points.
    7. Analyst Comment- Each of our analysts carries large pool of experience from domain perspective and add their value which is directional in nature
global-aesthetic-dermatology-market

To request a free sample copy of this report, please complete the form below verified and secure

We offer complete free customization that addresses client’s need. This includes insights from primary market research and a 60-minute free analyst consultation post report purchase.

This website is secure and your personal details are safe. Privacy policy

Description

The global Bipolar Disorder Market was valued at $5.8 Billion in 2017 and is forecast to grow at a modest3.1 % CAGR between 2018 and 2025, culminating in 2025 global sales of $XXX.64 Billion.

 

Symptoms of bipolar disorder is a mental illness characterized by an extreme shift in mood, can include an extremely elevated mood called mania. It can have an episode of depression. People with bipolar disorder can have serious trouble managing daily life at office, school or work. As per the national institute of mental health (NIMH), 2.8% of U.S. adult have diagnosed with bipolar disorder and 4.4% have experienced at sometime in their lives.

 

There are 3 main symptoms of bipolar disorder as mania, hypomania, and depression. Mania will lead to emotional high as unprotected sex, drug use etc. whereas hypomania will cause deep sadness, hopelessness, lack of interest in activities and suicidal thoughts. During the study, we observed a steep rise in the incidence of bipolar disorder in 5 states of USA, Germany, UK, Greece, Italy, and Spain. Though we have not noticed any major difference in trend between male and female, female will have a more frequent relapse due to hormonal changes.

 

Though the cause of bipolar disorder is not properly known to physicians, possible factors could be your genetics, abnormalities in the brainand environmental factor. There is no cure for bipolar disorder, but medications are there to control symptoms. It might need a combination of medication, physiotherapy, and psychoeducation.

 

Global Bipolar Disorder Market Outlook To 2025

 

Pricing Analysis

 

“Optimal Price Point (OPP) for Bipolar Disorder Drugs”

 

Estimated Average bipolar disorder drugs cost – $ xx globally. However, with improving access and availability of options, OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.

 

Product affordability and access to healthcare facilities are key variables impacting the market growth. The high demand for bipolar disorder drugs and other physiotherapy techniques in emerging nations is expected to drive the usage rates. The growing need for early diagnosis and government initiative is expected to lower the costs and improve the purchasing power of patients in this region.

 

Bipolar Disorder Market by “Drug Class”

 

Based on drug class, the market is segmented as Mood stabilizer, Anticonvulsant, Antipsychotic, Antidepressant, Antianxiety. Usage of tricyclic antidepressants for bipolar disorder has declined over the years due to its side effect profile. More than 60% of the market is dominated by antipsychotic drugs such as Aripiprazole (Abilify), Asenapine (Saphris), Olanzapine (Zyprexa), Quetiapine (Seroquel), Risperidone (Risperdal) etc. Some of the prominent mood stabilizers for bipolar disorder are Lithium, Valproate (Depakote), Carbamazepine (Tegretol), Gabapentin (Neurontin) etc. Carbamazepine is not approved by U.S. FDA but extensively used for bipolar disorder. Anticonvulsants work by calming hyperactivity and prescribed alone or in combination with antipsychotic drugs.

 

Bipolar Disorder Market by “Mechanism of Action”

 

Based on the mechanism of actions, the market is segmented as Dopaminergic neurotransmission inhibition, Selective serotonin reuptake inhibitor (SSRI), Serotonin-norepinephrine reuptake inhibitor (SNRI), Tricyclic antidepressants, Monoamine oxidase inhibitor, Benzodiazepines, Beta blockers, Others. All antipsychotic drugs dominating treatment for bipolar disorder by Dopaminergic neurotransmission Inhibition. Selective serotonin reuptake inhibitors (SSRIs) ease depression by increasing serotonin level in the brain. Benzodiazepines are not considered as the1st line of treatment but prescribed in combination with other drugs to control the maniac symptoms.

 

Regional Segmentation

 

In 2017, North America was the leading region by revenue owing to factors such as thepresence of well-developed hospital and diagnostic center network, thehighrate of diagnosis, transparent process for availing reimbursement, and high emphasis on research & development. The U.S. alone accounts for over 80% share in North America. The U.S. spends nearly 3.2 trillion dollars or 17% of GDP toward healthcare expenditure, to provide the best possible infrastructure and technology solutions to patients living in the region.

 

Asia Pacific is expected to register the maximum CAGR of over 7.2% over the forecast period with greater demand from geriatric population of China. High unmet needs, growing healthcare expenditure, and an increasingnumber of hospitals and psychiatric centers are anticipated to significantly drive the demand for bipolar disorder drugs over the next few years.

 

Top Players & Company Share

 

Key players operating in the market include Pfizer Inc., Janssen Pharmaceuticals,Glaxo SmithKline (GSK), AstraZeneca, Eli Lilly, Allergan Plc., Novartis AG, AbbVie Inc. and Otsuka Holdings Co. Ltd.Due to high entry barriers, such as high capital costs, technology and IPR rights, and brand building efforts, the number of new entrants is usually low in the market. However, the startups are working on integrating connectivity technologies, newer designing and other niche areas to improve the product and service offerings.

The launch of Vraylarfrom Allergan in 2016 for bipolar disorder shows the attractiveness of this market.

 

Market Segmentation

 

Bipolar Disorder Market byDrug Class(Revenue, Million, 2014 – 2025)

  • Mood stabilizer
  • Anticonvulsant
  • Antipsychotic
  • Antidepressant
  • Antianxiety

 

Bipolar Disorder Market by Mechanism of Action, (Revenue, USD Million, 2014 – 2025)

  • Dopaminergic neurotransmission inhibition
  • Selective serotonin reuptake inhibitor
  • Serotonin-norepinephrine reuptake inhibitor
  • Tricyclic antidepressants
  • Monoamine oxidase inhibitor
  • Benzodiazepines
  • Beta-blockers
  • Others

Bipolar Disorder Market Regional Outlook (Revenue, USD Million, 20124- 2025)

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
  • Asia Pacific
    • Japan
    • China
    • India
  • Latin America
    • Brazil
    • Mexico
    • Columbia
  • Middle East and Africa
    • South Africa
    • Saudi Arabia

 

Bipolar Disorder Market, Bipolar Disorder Market Analytics, Bipolar Disorder Market Share, Bipolar Disorder Market Research, Bipolar Disorder Market Forecast, Bipolar Disorder Market Insight, Bipolar Disorder Market Trend, Bipolar Disorder Market Value,Bipolar Disorder Market Size, Bipolar Disorder Market Analysis, Bipolar Disorder Market Survey, Bipolar Disorder Market Research Report

Additional information

Price

Single User $5,650, Multiple User $8,650, Enterprise User $12,650